ClinicaliQ Trial Snapshot
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. — Recruiting • Phase III • Diabetes / Metabolic • NCT07753993.
- What is being tested: Elecoglipron (a novel therapeutic agent) versus placebo in adults with chronic kidney disease, with or without type 2 diabetes, all receiving background SGLT2 inhibitor therapy (dapagliflozin) and standard of care treatments.
- Patient eligibility overview: The trial includes adult participants with CKD stratified by diabetes status (with and without T2DM), who are already established on SGLT2 inhibitor therapy as part of their guideline-directed medical management.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Eligibility Snapshot
- : * Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges. * On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.